Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506524 | 1.00 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506459 | 0.95 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373288 | 0.95 | WEE1 (0.59) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373403 | 0.93 | WEE1 (0.61) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506521 | 0.93 | WEE1 (0.61) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373416 | 0.92 | WEE1 (0.68) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL29506525 | 0.92 | WEE1 (0.68) | WEE1KCNH2BRD4EGFRSIK2 | |
| SCHEMBL21373301 | 0.92 | WEE1 (0.63) | WEE1KCNH2SIK2TNK2 | |
| SCHEMBL29506515 | 0.92 | WEE1 (0.63) | WEE1KCNH2SIK2TNK2 | |
| SCHEMBL21373390 | 0.91 | WEE1 (0.69) | WEE1KCNH2BRD4EGFRSIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | claimed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | claimed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | claimed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | claimed |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | claimed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | claimed |
| EP-3543242-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | Impact Therapeutics, Inc (CN) | 2019-09-25 | — | — | EP | claimed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | disclosed |
| EP-3543242-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | Impact Therapeutics, Inc (CN) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | WEE1 1/4885KCNH2 2265/4885BRD4 1532/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | WEE1 1/4885KCNH2 2265/4885BRD4 1532/4885 |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | WEE1, WEE2, EZH2 | WEE1 1/4885KCNH2 3809/4885BRD4 124/4885 |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | WEE1 1/4885KCNH2 2265/4885BRD4 1532/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | WEE1 1/4885KCNH2 2265/4885BRD4 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.